Access · International

[2026 update] Availability by country, dated, with primary sources

Access › International MHRA NHS telehealth personal import

m.ibarraTL2 Moderator10 Dec 2025#1

On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion.

Documenting an access outcome, dated, because everything in this category expires.

As of March 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

23 likes 8mo

s.teixeiraTL2 Moderator15 Dec 2025#2

I read the opening post twice before replying, because I had assumed the opposite.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

25 likes 7mo

revision_historyTL3Wiki editor19 Dec 2025#3

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

0 likes 7mo

m.ilungaTL2 Moderator23 Dec 2025#4

revision_history, post #3: Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary. Go to post

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

1 like in reply to #3 7mo

g.valckenaereTL3Regular26 Dec 2025#5

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

18 likes 7mo

a.lindqvistTL2 Moderator29 Dec 2025#6

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

0 likes 7mo

desiccant_notesTL2Member1 Jan 2026#7

post #6 answers the question as asked. The question underneath it is different.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

0 likes 7mo

s.roosTL2 Moderator3 Jan 2026 · edited#8

a.lindqvist, post #6: Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks. Go to post

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

4 likes in reply to #6 7mo

LeitermanTL3Regular6 Jan 2026 · edited#9

m.ilunga, post #4: Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk. Go to post

This follows post #6 rather than contradicting it.

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

4 likes in reply to #4 7mo

g.ekstromTL2 Moderator9 Jan 2026#10

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

13 likes 7mo

j.fonsecaTL2 Moderator11 Jan 2026 · edited#11

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

0 likes 7mo

dr_okonkwoTL4 Moderator14 Jan 2026#12

post #11 is right about the mechanism and I think understates the practical bit.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

24 likes 6mo

n.brobergTL2 Moderator16 Jan 2026#13

I read post #11 twice before replying, because I had assumed the opposite.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

7 likes in reply to #4 6mo

PharmNotes_WhitfieldTL4Pharmacist18 Jan 2026#14

m.ibarra, post #1: On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of March 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it,… Go to post

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

1 like in reply to #1 6mo

p.mwangiTL2 Moderator21 Jan 2026#15

On post #11 — agreed on the reasoning, with one qualification.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

0 likes 6mo

orbitrap_olaTL3Mass spectrometrist23 Jan 2026#16

post #15 answers the question as asked. The question underneath it is different.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

17 likes 6mo

ro.friskTL2 Moderator25 Jan 2026#17

4 likes 6mo

dr_seongTL328 Jan 2026#18

Collapsed as off-topic by two members at trust level 3 or above

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

z.laurentTL2 Moderator30 Jan 2026#19

Worth separating two things that post #15 runs together.

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

25 likes 6mo

d.yilmazTL2 Moderator1 Feb 2026#20

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

12 likes 6mo

a.nwosuTL2 Moderator3 Feb 2026#21

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

31 likes in reply to #4 6mo

a.batistaTL2 Moderator5 Feb 2026#22

Leiterman, post #9: This follows post #6 rather than contradicting it. Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials). Go to post

0 likes in reply to #9 6mo

a.novakTL2 Moderator7 Feb 2026 · edited#23

Picking up post #20: that is the part I would want checked first.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

3 likes 6mo

bench_notesTL4 Moderator10 Feb 2026#24

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Coming back to post #22, because the follow-up matters more than the original answer.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

11 likes 6mo

e.vargaTL2 Moderator12 Feb 2026#25

post #24 is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

0 likes 5mo

r.aldana_pharmdTL4Pharmacist14 Feb 2026#26

s.roos, post #8: Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

1 like in reply to #8 5mo

s.okaforTL2 Moderator16 Feb 2026#27

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

6 likes 5mo

lc_gradientTL3Analytical chemist18 Feb 2026#28

I read post #26 twice before replying, because I had assumed the opposite.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

16 likes 5mo

d.vukovicTL2 Moderator20 Feb 2026#29

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

17 likes 5mo

dr_bhattacharyaTL3Physician22 Feb 2026#30

On post #26 — agreed on the reasoning, with one qualification.

32 likes in reply to #6 5mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →